Sevalamer Hydrochloride, Sevelamer Carbonate and Lanthanum Carbonate: In Vitro and In Vivo Effects on Gastric Environment

Therapeutic Apheresis and Dialysis

Volumn 19, Issue 5, 2015, Pages 471-476

  Coppolino, Giuseppe ^a   Lucisano, Silvia ^b   Rivoli, Laura ^a   Fuiano, Giorgio ^a   Villari, Antonino ^b   Villari, Iole ^b   Leonello, Grazia ^b   Lacquaniti, Antonio ^b   Santoro, Domenico ^b   Buemi, Michele ^b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Chronic kidney disease; Gastrointestinal disorders; Hyperphosphatemia; Phosphate binders

Indexed keywords

CARBON DIOXIDE; LANSOPRAZOLE; LANTHANUM CARBONATE; PHOSPHORIC ACID; PHOSPHORUS; SEVELAMER; SEVELAMER CARBONATE; CHELATING AGENT; LANTHANUM; PROTON PUMP INHIBITOR;

AGED; ALKALINITY; ALKALINIZATION; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISSOLUTION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROESOPHAGEAL REFLUX; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; IN VITRO STUDY; IN VIVO STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH PH; COMPARATIVE STUDY; DRUG EFFECTS; DRUG RELEASE; DRUG TOLERANCE; METABOLISM; PH; RENAL REPLACEMENT THERAPY; STOMACH;

AGED; CARBON DIOXIDE; CHELATING AGENTS; DRUG LIBERATION; DRUG TOLERANCE; FEMALE; GASTRIC ACIDITY DETERMINATION; HUMANS; HYDROGEN-ION CONCENTRATION; LANTHANUM; MALE; PHOSPHORUS; PROTON PUMP INHIBITORS; RENAL DIALYSIS; SEVELAMER; STOMACH;

EID: 84945478357     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/1744-9987.12305     Document Type: Article

References (22)

1. Kestenbaum B, Sampson JN, Rudser KD etal. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005;16:520-528.
2. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-2218.
3. Coppolino G, Bolignano D, De Paola L etal. Parathyroid hormone and mobilization of circulating bone marrow-derived cells in uremic patients. J Investig Med 2011;59:823-828.
4. Raggi P, Kleerekoper M. Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008;3:836-843.
5. Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med 2010;362:1312-1324.
6. Senatore M, Coppolino G, Papalia T, Greco R, Lofaro D, Bonofiglio R. Does concomitant administration of sevelamer hydrochloride and lanthanum carbonate modify the control of phosphatemia? Eur Rev Med Pharmacol Sci 2011;15:1352-1354.
7. Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 2009;54:619-637.
8. Kovesdy CP, Kuchmak O, Lu JL, Kalantar-Zadeh K. Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD. Am J Kidney Dis 2010;56:842-851.
9. Qunibi WY, Hootkins RE, McDowell LL etal. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 2004;65:1914-1926.
10. Williams RL. Standards-setting activities of the US pharmacopeia during the 2000-2005 cycle. Drug Inf J 2006;40:317-329.
11. United States Pharmacopeial Convention. Board of Trustees, United States Pharmacopeial Convention. Committee of Revision, National Formulary Board: The United States Pharmacopeia. Supplement. National Formulary. Rockville, MD: United States Pharmacopeial Convention, 2009; v.
12. Buemi M, Coppolino G, Sturiale A etal. Cinacalcet modifies the pH of solutions in vitro: possible implications for gastro-intestinal side effects in vivo. Nephrol Dial Transplant 2007;22:2409-2411.
13. Hakata T, Iijima M, Okabe T etal. Methods of evaluation of release of carbon dioxide from effervescent suppositories. Chem Pharm Bull (Tokyo) 1993;41:346-350.
14. Zentilin P, Iiritano E, Dulbecco P etal. Normal values of 24-h ambulatory intraluminal impedance combined with pH-metry in subjects eating a Mediterranean diet. Dig Liver Dis 2006;38:226-232.
15. Swidnicka-Siergiejko A, Dabrowski A. Prolonged 2-day esophageal pH-metry with impedance monitoring improves symptom-reflux association analysis. Dig Dis Sci 2013;58:2556-2563.
16. Shay S, Tutuian R, Sifrim D etal. Twenty-four hour ambulatory simultaneous impedance and pH monitoring: a multicenter report of normal values from 60 healthy volunteers. Am J Gastroenterol 2004;99:1037-1043.
17. Sifrim D, Castell D, Dent J, Kahrilas PJ. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut 2004;53:1024-1031.
18. Swearingen RA, Chen X, Petersen JS, Riley KS, Wang D, Zhorov E. Determination of the binding parameter constants of Renagel capsules and tablets utilizing the Langmuir approximation at various pH by ion chromatography. J Pharm Biomed Anal 2002;29:195-201.
19. Boeckxstaens GE, Smout A. Systematic review: role of acid, weakly acidic and weakly alkaline reflux in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2010;32:334-343.
20. Muto S, Murayama N, Asano Y, Hosoda S, Miyata M. Hypergastrinemia and achlorhydria in chronic renal failure. Nephron 1985;40:143-148.
21. Fu RG, Wang Y, Yuan HZ etal. Effects of chronic renal failure on gastrointestinal motility: a study on the changes of gastric emptying, small intestinal transit, interdigestive myoelectric complex, and fecal water content. Ren Fail 2011;33:615-621.
22. Ko CW, Chang CS, Lien HC, Wu MJ, Chen GH. Gastric dysrhythmia in uremic patients on maintenance hemodialysis. Scand J Gastroenterol 1998;33:1047-1051.